Применение гиалуроновой кислоты при вульвовагинальной атрофии у женщин после противоопухолевого лечения

1. Pérez-López F.R., Phillips N., Vieira-Baptista P., Cohen-Sacher B., Fialho S.C.A.V., Stockdale C.K. Management of postmenopausal vulvovaginal atrophy: recommendations of the International society for the study of vulvovaginal disease. Gynecol. Endocrinol. 2021; 37(8): 746-52.https://dx.doi.org/10.1080/09513590.2021.1943346
2. Lev-Sagie A. Vulvar and vaginal atrophy: physiology, clinical presentation, and treatment considerations. Clin. Obs. Gynecol. 2015; 58(3): 476-91. https://dx.doi.org/10.1097/GRF.0000000000000126
3. Gliniewicz K., Schneider G.M., Ridenhour B.J., Williams C.J., Song Y., Farage M.A. et al. Comparison of the vaginal microbiomes of premenopausal and postmenopausal women. Front. Microbiol. 2019; 10: 193. https://dx.doi.org/10.3389/fmicb.2019.00193
4. Brotman R.M., Shardell M.D., Gajer P., Fadrosh D., Chang K., Silver M.I. et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause. 2014; 21: 450-8. https://dx.doi.org/10.1097/GME.0b013e3182a4690b
5. Nappi R.E., Cucinella L., Martini E., Cassani C. The role of hormone therapy in urogenital health after menopause. Best Pract. Res. Clin. Endocrinol. Metab. 2021; 35: 101595. https://dx.doi.org/10.1016/j.beem.2021.101595
6. Escobar C., Rosenblum N. Vaginal estrogen-what a urologist should know. Urology. 2021; 151: 37-43. https://dx.doi.org/10.1016/j.urology.2020.05.034
7. Cox P., Panay N. Vulvovaginal atrophy in women after cancer. Climacteric. 2019; 22(6): 565-71. https://dx.doi.org/10.1080/13697137.2019.1643180
8. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020; 27(9): 976-92. https://dx.doi.org/10.1097/GME.0000000000001609
9. Gambacciani M. Managing vulvovaginal atrophy after breast cancer. Post Reprod. Health. 2019; 25(3): 167-8. https://dx.doi.org/10.1177/2053369119848884
10. Meriggiola M.C., Villa P., Maffei S., Becorpi A., Di Paolantonio T., Nicolucci A. et al. Vulvovaginal atrophy in women with and without a history of breast cancer: baseline data from the Patient satisfaction study (PEONY) in Italy. Maturitas. 2024; 183: 107950. https://dx.doi.org/10.1016/j.maturitas.2024.107950
11. Guidozzi F. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation. Climacteric. 2016; 19(5): 419-22. https://dx.doi.org/10.1080/13697137.2016.1209396
12. Kelsey T.W., Hua C.H., Wyatt A., Indelicato D., Wallace W.H. A predictive model of the effect of therapeutic radiation on the human ovary. PLOS One. 2022; 17(11): e0277052. https://dx.doi.org/10.1371/journal.pone.0277052
13. Huang Y., Qin T., Yang M., Liu Z. Impact of ovary-sparing treatment planning on plan quality, treatment time and gamma passing rates in intensity-modulated radiotherapy for stage I/II cervical cancer. Medicine (Baltimore). 2023; 102(50): e36373. https://dx.doi.org/10.1097/MD.0000000000036373
14. Moss E.L., Taneja S., Munir F., Kent C., Robinson L., Potdar N. et al. Iatrogenic menopause after treatment for cervical cancer. Clin. Oncol. (R. Coll. Radiol.). 2016; 28(12): 766-75. https://dx.doi.org/10.1016/j.clon.2016.08.016
15. Panay N., Fenton A. Iatrogenic menopause following gynecological malignancy: time for action! Climacteric. 2016; 19(1): 1-2. https://dx.doi.org/10.3109/13697137.2015.1127640
16. Kollberg K.S., Waldenström A.-C., Bergmark K., Dunberger G., Rossander A., Wilderäng U. et al. Reduced vaginal elasticity, reduced lubrication, and deep and superficial dyspareunia in irradiated gynecological cancer survivors. Acta Oncol. 2015; 54(5): 772-9. https://dx.doi.org/10.3109/0284186X.2014.1001036
17. Jensen P.T., Froeding L.P. Pelvic radiotherapy and sexual function in women. Transl. Androl. Urol. 2015; 4(2): 186-205. https://dx.doi.org/10.3978/j.issn.2223-4683.2015.04.06
18. Джанашвили Л.Г., Назаренко Т.А., Балахонцева О.С., Мартиросян Я.О., Пронин С.М., Калинина Е.А., Бирюков А.М. Реализация репродуктивной функции у больных с атипической гиперплазией и раком эндометрия I стадии. Акушерство и гинекология. 2020; 4: 45-51.
19. Кутаков Н.М., Чекини Д.А. Перспективы и возможности сохранения репродуктивной функции у больных, получающих противоопухолевое лечение. Клиническое наблюдение. MD-Onco. 2023; 3(2): 16-9.
20. Назаренко Т.А., Сухих Г.Т., ред. Сохранение репродуктивной функции онкологических больных. Руководство для врачей. М.: МЕДпресс-информ; 2022. 160 с.
21. Claes M., Tuts L., Robijns J., Mulders K., Van De Werf E., Bulens P. et al. Cancer therapy-related vaginal toxicity: its prevalence and assessment methods – a systematic review. J. Cancer Surviv. 2024; 19: 1293-312. https://dx.doi.org/10.1007/s11764-024-01553-y
22. Cotangco K., Class Q.A., Johnson T.P., Kothari R. Cervical cancer survivors’ attitudes and understanding of menopause and hormone therapy. Menopause. 2020; 27(6): 701-5. https://dx.doi.org/10.1097/GME.0000000000001520
23. Hofsjö A., Bergmark K., Blomgren B., Jahren H., Bohm-Starke N. Radiotherapy for cervical cancer – impact on the vaginal epithelium and sexual function. Acta Oncol. 2018; 57(3): 338-45. https://dx.doi.org/10.1080/0284186X.2017.1400684
24. Tramacere F., Lancellotta V., Casà C., Fionda B., Cornacchione P., Mazzarella C. et al. Assessment of sexual dysfunction in cervical cancer patients after different treatment modality: a systematic review. Medicina (Kaunas). 2022; 58(9): 1223. https://doi.org/10.3390/medicina58091223
25. Kirchheiner K., Smet S., Jürgenliemk-Schulz I.M., Haie-Meder C., Chargari C., Lindegaard J.C. et al. Impact of vaginal symptoms and hormonal replacement therapy on sexual outcomes after definitive chemoradiotherapy in patients with locally advanced cervical cancer: results from the EMBRACE-I study. Int. J. Radiat. Oncol. Biol. Phys. 2022; 112(2): 400-13. https://doi.org/10.1016/j.ijrobp.2021.08.036
26. Мкртчян Л.С., Иванов С.А., Кулиева Г.З.К., Замулаева И.А., Крикунова Л.И. Улучшение качества жизни больных раком шейки матки после лучевой т химиолучевой терапии. Радиация и риск (Бюллетень НРЭР). 2020; 1(29): 120-8.
27. Rees M., Angioli R., Coleman R.L., Glasspool R., Plotti F., Simoncini T. et al. European menopause and andropause society (EMAS) and International gynecologic cancer society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas. 2020; 134: 56-61. https://dx.doi.org/10.1016/j.maturitas.2020.01.005
28. Filippini M., Porcari I., Ruffolo A.F., Casiraghi A., Farinelli M., Uccella S. et al. CO2-Laser therapy and genitourinary syndrome of menopause: a systematic review and meta-analysis. J. Sex. Med. 2022; 19(3): 452-70. https://dx.doi.org/10.1016/j.jsxm.2021.12.010
29. Benini V., Ruffolo A.F., Casiraghi A., Degliuomini R.S., Frigerio M., Braga A. et al. New innovations for the treatment of vulvovaginal atrophy: an up-to-date review. Medicina (Kaunas). 2022; 58(6): 770. https://dx.doi.org/10.3390/medicina58060770
30. Desai S.A., Kroumpouzos G., Sadick N. Vaginal rejuvenation: from scalpel to wands. Int. J. Womens Dermatol. 2019; 5(2): 79-84. https://dx.doi.org/10.1016/j.ijwd.2019.02.003
31. Cox P., Panay N. Non-hormonal treatments for managing vulvovaginal atrophy/genitourinary syndrome of menopause. Climacteric. 2023; 26(4): 367-72. https://dx.doi.org/10.1080/13697137.2023.2210283
32. Woopen H., Sehouli J., Davis A., Lee Y.C. , Cohen P.A., Ferrero A. et al. GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: a position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee. Cancer Treat. Rev. 2022; 107: 102396. https://dx.doi.org/10.1016/j.ctrv.2022.102396
33. Faubion S.S., Larkin L.C., Stuenkel C.A., Bachmann G.A., Chism L.A., Kagan R. et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: Consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 2018; 25(6): 596-608. https://dx.doi.org/10.1097/GME.0000000000001121
34. Kuhle C.L., Kapoor E., Sood R., Thielen J.M., Jatoi A., Faubion S.S. Menopausal hormone therapy in cancer survivors: a narrative review of the literature. Maturitas. 2016; 92: 86-96. https://dx.doi.org/10.1016/j.maturitas.2016.07.018
35. Sassarini J., Perera M., Spowart K., McAllister K., Fraser J., Glasspool R. et al. Managing vulvovaginal atrophy after breast cancer. Post Reprod. Health. 2018; 24(4): 163-5. https://dx.doi.org/10.1177/2053369118805344
36. Министерство здравоохранения Российской Федерация. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. М.; 2024. 93 с.
37. Marès P., Jauffret C., Martin C., Lopes P., Coussy F. Genitourinary syndrome of menopause in patients with breast cancer treated by hormonotherapy: women's perception in ITAC, a French web-based survey. Bull. Cancer. 2024; 111(4): 347-55. https://dx.doi.org/10.1016/j.bulcan.2023.08.014
38. Pruthi S., Simon J.A., Early A.P. Current overview of the management of urogenital atrophy in women with breast cancer. Breast J. 2011; 17(4): 403-8. https://dx.doi.org/10.1111/j.1524-4741.2011.01089.x
39. Faubion S.S., Larkin L.C., Stuenkel C.A., Bachmann G.A., Chism L.A., Kagan R. et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 2018; 25(6): 596-608. https://dx.doi.org/10.1097/GME.0000000000001121
40. Concin N., Matias-Guiu X., Vergote I., Cibula D., Mirza M.R., Marnitz S. et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer. 2021; 31(1): 12-39. https://dx.doi.org/10.1136/ijgc-2020-002230
41. Chargari C., Tanderup K., Planchamp F., Chiva L., Humphrey P., Sturdza A. et al. ESGO / ESTRO quality indicators for radiation therapy of cervical cancer. Int. J. Gynecol. Cancer. 2023; 33(6): 862-75. https://dx.doi.org/10.1136/ijgc-2022-004180
42. Dicker K.T., Gurski L.A., Pradhan-Bhatt S., Witt R.L., Farach-Carson M.C., Jia X. Hyaluronan: a simple polysaccharide with diverse biological functions. Acta Biomater. 2014; 10(4): 1558-70. https://dx.doi.org/10.1016/j.actbio.2013.12.019
43. Al Ghanim K., Jaszkul K.M., Simpson A., Turley E.A. Association of squamous cell carcinoma and hyaluronan: a scope of the literature. Eplasty. 2024; 24: e11.
44. Tavianatou A.G., Caon I., Franchi M., Piperigkou Z., Galesso D., Karamanos N.K. Hyaluronan: molecular size-dependent signaling and biological functions in inflammation and cancer. FEBS J. 2019; 286(15): 2883-2908. https://dx.doi.org/10.1111/febs.14777
45. Fallacara A., Baldini E., Manfredini S., Vertuani S. Hyaluronic acid in the third millennium. Polymers (Basel). 2018; 10(7): 701. https://dx.doi.org/10.3390/polym10070701
46. Garantziotis S., Savani R.C. Hyaluronan biology: a complex balancing act of structure, function, location and context. Matrix Biol. 2019; 78-79: 1-10. https://dx.doi.org/10.1016/j.matbio.2019.02.002
47. Parnigoni A., Moretto P., Rovera S., Viola M., Karousou E., Passi A. et al. Particle exclusion assay: a tool for measuring hyaluronan pericellular matrix. Methods Mol. Biol. 2023; 2619: 53-60. https://dx.doi.org/10.1007/978-1-0716-2946-8_4
48. Tolg C., Messam B.J., McCarthy J.B., Nelson A.C., Turley E.A. Hyaluronan functions in wound repair that are captured to fuel breast cancer progression. Biomolecules. 2021; 11(11): 1551. https://dx.doi.org/10.3390/biom11111551
49. Price Z.K., Lokman N.A., Ricciardelli C. Differing roles of hyaluronan molecular weight on cancer cell behavior and chemotherapy resistance. Cancers (Basel). 2018; 10(12): 482. https://dx.doi.org/10.3390/cancers10120482
50. Albtoush N., Queisser K.A., Zawerton A., Lauer M.E., Beswick E.J., Petrey A.C. TSG6 hyaluronan matrix remodeling dampens the inflammatory response during colitis. Matrix Biol. 2023; 121: 149-66. https://dx.doi.org/10.1016/j.matbio.2023.06.007
51. Triggs-Raine B., Natowicz M.R. Biology of hyaluronan: insights from genetic disorders of hyaluronan metabolism. World J. Biol. Chem. 2015; 6(3): 110-20. https://dx.doi.org/10.4331/wjbc.v6.i3.110
52. Шнайдер Н.А., Дюжакова А.В., Вайман Е.Э., Никитина Е.И., Борзых О.Б., Насырова Р.Ф. Значение генетических факторов метаболизма эндогенной гиалуроновой кислоты в поддержании гомеостаза кожи. Вестник дерматологии и венерологии. 2021; 97(3): 24-38.
53. Kobayashi T., Chanmee T., Itano N. Hyaluronan: metabolism and function. Biomolecules. 2020; 10(11): 1525. https://dx.doi.org/10.3390/biom10111525
54. Cirillo N. The hyaluronan/CD44 axis: a double-edged sword in cancer. Int. J. Mol. Sci. 2023; 24(21): 15812. https://dx.doi.org/10.3390/ijms242115812
55. Матчук О.Н., Замулаева И.А. Количественные изменения популяции стволовых клеток рака шейки матки линии Hela под влиянием фракционированного γ-облучения in vitro. Радиация и риск. 2019; 28(2): 112-23.
56. Замулаева И.А., Матчук О.Н., Селиванова Е.И., Андреев В.Г., Липунов Н.М., Макаренко С.А., Жаворонков Л.П., Саенко А.С. Увеличение количества опухолевых стволовых клеток под воздействием редкоионизирующего излучения. Радиационная биология. Радиоэкология. 2014; 54(3): 256-64.
57. Peitzch C., Kurth I., Ebert N., Dubrovska A., Baumann M. Cancer stem cells in radiation response: current views and future perspectives in radiation oncology. Int. J. Radiat. Biol. 2019; 95(7): 900-11. https://dx.doi.org/10.1080/09553002.2019.1589023
58. Phi L., Sari I., Yang Y.-G., Lee S.-H., Jun N., Kim K.S. et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018; 2018: 5416923. https://dx.doi.org/10.1155/2018/5416923
59. Zamulaeva I.A., Selivanova E.I., Matchuk O.N., Krikunova L.I., Mkrtchyan L.S., Kulieva G.Z. et al. Quantitative changes in the population of cancer stem cells after radiation exposure in a dose of 10 gy as a prognostic marker of immediate results of the treatment of squamous cell cervical cancer. Bull. Exp. Biol. Med. 2019; 168(1): 156-9. https://dx.doi.org/10.1007/s10517-019-04667-x
60. Zamulaeva I., Matchuk O., Selivanova E., Mkrtchian L., Yakimova A., Gusarova V. et al. Effects of fractionated radiation exposure on vimentin expression in cervical cancers: analysis of association with cancer stem cell response and short-term prognosis. Int. J. Mol. Sci. 2023; 24(4): 3271. https://dx.doi.org/10.3390/ijms24043271
61. Lytle N.K., Barber A.G., Reya T. Stem cells fate in cancer growth, progression and therapy resistance. Nat. Rev. Cancer. 2018; 18(11): 669-80. https://dx.doi.org/10.1038/s41568-018-0056-x
62. Palomeras S., Ruiz-Martínez S., Puig T. Targeting breast cancer stem cells to overcome treatment resistance. Molecules. 2018; 23(9): 2193. https://dx.doi.org/10.3390/molecules23092193
63. Luo M., Clouthier S.G., Deol Y., Liu S., Nagrath S., Azizi E. et al. Breast cancer stem cells: current advances and clinical implications. Methods Mol Biol. 2015; 1293: 1-49. https://dx.doi.org/10.1007/978-1-4939-2519-3_1
64. Yang F., Xu J., Tang L., Guan X. Breast cancer stem cell: the roles and therapeutic implications. Cell. Mol. Life Sci. 2017; 74(6): 951-66. https://dx.doi.org/10.1007/s00018-016-2334-7
65. Chanmee T., Ontong P., Kimata K., Itano N. Key roles of hyaluronan and its CD44 receptor in the stemness and survival of cancer stem cells. Front. Oncol. 2015; 5: 180. https://dx.doi.org/10.3389/fonc.2015.00180
66. Bourguignon L.Y.W., Shiina M., Li J.J. Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression. Adv. Cancer Res. 2014; 123: 255-75. https://dx.doi.org/10.1016/B978-0-12-800092-2.00010-1
67. Киселёва М.В., Замулаева И.А., Радзинский В.Е., Оразов М.Р., Долгов Е.Д., Иванов С.А., Каприн А.Д. Новый метод лечения вульвовагинальной атрофии у пациенток с отягощенным онкологическим анамнезом. Вопросы гинекологии, акушерства и перинатологии. 2024; 23(3):111-7.
68. Liu Z., Hou P., Fang J., Shao C., Shi Y., Melino G. et al. Hyaluronic acid metabolism and chemotherapy resistance: recent advances and therapeutic potential. Mol. Oncol. 2024; 18(9): 2087-2106. https://dx.doi.org/10.1002/1878-0261.13551
69. Bourguignon L.Y.W., Earle C., Shiina M. Hyaluronan-CD44 interaction promotes HPV 16 E6 oncogene-mediated oropharyngeal cell carcinoma survival and chemoresistance. Matrix Biol. 2019; 78-79: 180-200.https://dx.doi.org/10.1016/j.matbio.2018.07.008
70. Cascone S., Lamberti G. Hydrogel-based commercial products for biomedical applications: a review. Int. J. Pharm. 2020; 573: 118803. https://dx.doi.org/10.1016/j.ijpharm.2019.118803

Поступила 15.07.2025

Принята в печать 13.08.2025